USA - NASDAQ:CERO - US71902K4022 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to CERO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-03 | Maxim Group | Downgrade | Buy -> Hold |
| 2025-10-30 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-04 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-23 | D. Boral Capital | Upgrade | Hold -> Buy |
| 2025-05-30 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2025-05-19 | Maxim Group | Initiate | Buy |
| 2025-04-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-22 | D. Boral Capital | Initiate | Buy |
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
The consensus rating for CERO THERAPEUTICS HOLDINGS I (CERO) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering CERO THERAPEUTICS HOLDINGS I (CERO) is 8.